Antibody response to unconjugated Haemophilus influenzae b and pneumococcal polysaccharide vaccines in children with recurrent infections.
BACKGROUND
Increasingly, antibody testing is being used to evaluate the status of humoral immunity in patients with recurrent infection and suspected immunodeficiency. In the past, we had been impressed that immunization with unconjugated Haemophilus influenzae b (uHib) vaccine provided useful information about the ability to produce antibody to polysaccharides and that the use of pneumococcal polysaccharide (PPS) vaccine frequently produced results that were difficult to interpret.


OBJECTIVE
The study was carried out to compare antibody responsiveness to vaccination with uHib with the response seen after PPS vaccination.


METHODS
Twenty children (ages, 2 to 13 years; 11 male) who were referred to our immunology clinic because of recurrent infections were immunized with both uHib vaccine and PPS vaccine. Nine children had previously received conjugated Hib vaccine.


RESULTS
All 20 children either responded with a twofold or greater increase in antibody titer after uHib vaccine or had preimmunization antibody concentrations of greater than 400 nanograms antibody nitrogen per milliliter (ng Ab N/ml). All of the children responded to PPS-3 with postimmunization antibody concentrations greater than 400 ng Ab N/ml. Three children had an increase in titer to PPS-7 of less than twofold, seven did not have a twofold increase in titer to PPS-9, and 15 had an increase in titer to PPS-14 of less than twofold.


CONCLUSIONS
Unconjugated Hib vaccine is a potent immunogen in children over 2 years of age. Prior immunization with the conjugate vaccine did not prevent a response to unconjugated vaccine. Unconjugated Hib vaccine appears to be at least as immunogenic as PPS-3 when used as an assessment vaccine for evaluating antibody responsiveness.
Raby
R
R
Department of Pediatrics, University of Tennessee, Memphis, USA.
Blaiss
M
M
Gross
S
S
Herrod
H G
HG
D000293:Adolescent; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001428:Bacterial Vaccines / Q000145:classification / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000145:classification; D008297:Male; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial / Q000145:classification / Q000276:immunology*; D012008:Recurrence; D012703:Serotyping
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial